- Home
- OSUR vs YMAB Comparison
OSUR vs YMAB Comparison
Compare OSUR & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- YMAB
- Stock Information
- Founded
- OSUR 2000
- YMAB 2015
- Country
- OSUR United States
- YMAB United States
- Employees
- OSUR N/A
- YMAB N/A
- Industry
- OSUR Medical/Dental Instruments
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- OSUR Health Care
- YMAB Health Care
- Exchange
- OSUR Nasdaq
- YMAB Nasdaq
- Market Cap
- OSUR 223.0M
- YMAB 218.4M
- IPO Year
- OSUR 1986
- YMAB 2018
- Fundamental
- Price
- OSUR $2.99
- YMAB $4.10
- Analyst Decision
- OSUR Hold
- YMAB Buy
- Analyst Count
- OSUR 2
- YMAB 11
- Target Price
- OSUR $5.50
- YMAB $18.73
- AVG Volume (30 Days)
- OSUR 624.9K
- YMAB 276.3K
- Earning Date
- OSUR 05-07-2025
- YMAB 05-06-2025
- Dividend Yield
- OSUR N/A
- YMAB N/A
- EPS Growth
- OSUR N/A
- YMAB N/A
- EPS
- OSUR N/A
- YMAB N/A
- Revenue
- OSUR $185,827,000.00
- YMAB $87,685,000.00
- Revenue This Year
- OSUR N/A
- YMAB N/A
- Revenue Next Year
- OSUR $7.55
- YMAB $21.10
- P/E Ratio
- OSUR N/A
- YMAB N/A
- Revenue Growth
- OSUR N/A
- YMAB 3.38
- 52 Week Low
- OSUR $2.69
- YMAB $3.84
- 52 Week High
- OSUR $5.59
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- OSUR 43.10
- YMAB 40.35
- Support Level
- OSUR $2.84
- YMAB $3.91
- Resistance Level
- OSUR $3.10
- YMAB $4.93
- Average True Range (ATR)
- OSUR 0.15
- YMAB 0.45
- MACD
- OSUR 0.02
- YMAB -0.03
- Stochastic Oscillator
- OSUR 37.50
- YMAB 16.25
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.